InMed Pharmaceuticals Inc
INM
Company Profile
Business description
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer’s disease, INM-089’s pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Contact
885 West Georgia Street
Suite 1445
VancouverBCV6C 3E8
CANT: +1 604 669-7207
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2025
Employees
13
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,806.40 | 64.50 | 0.74% |
| CAC 40 | 7,791.47 | 13.40 | -0.17% |
| DAX 40 | 24,174.32 | 130.14 | -0.54% |
| Dow JONES (US) | 42,761.76 | 1.11 | -0.00% |
| FTSE 100 | 8,832.28 | 5.63 | -0.06% |
| HKSE | 24,232.49 | 51.06 | 0.21% |
| NASDAQ | 19,591.24 | 61.28 | 0.31% |
| Nikkei 225 | 38,473.97 | 385.40 | 1.01% |
| NZX 50 Index | 12,572.34 | 33.08 | 0.26% |
| S&P 500 | 6,005.88 | 5.52 | 0.09% |
| S&P/ASX 200 | 8,581.20 | 65.50 | 0.77% |
| SSE Composite Index | 3,404.24 | 4.47 | 0.13% |